Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Fungal Infection Reports
Published in: Current Fungal Infection Reports 1/2014

01-03-2014 | Current Management of Fungal Infections (L Ostrosky-Zeichner, Section Editor)

Candida Sepsis: a New Entity?

Authors: Juan Pablo Caeiro, Fernando Riera

Published in: Current Fungal Infection Reports | Issue 1/2014

Login to get access

Abstract

Despite progress in the field of biological sciences, a definitive diagnosis of Candida sepsis remains an elusive target. Candida, which is frequently found in non-immunocompromised patients in intensive care units, causes severe sepsis, septic shock, and multiple-organ failure in a similar fashion as bacteria. Despite its imprecision, the blood and/or sterile-site culture is still the gold standard for diagnosis, although new biological markers are becoming available for earlier and more accurate diagnosis of invasive candidiasis. Mortality remains high due to a number of factors, and early initiation of appropriate antifungal therapy is a critical factor in positive outcomes. Echinocandins are the drug of choice for severe Candida infections in hospitalized patients. Antifungal stewardship programs may decrease the likelihood of resistance strains, and preventive measures are becoming available to lower the rate of fungal infections in intensive care units.
Literature
1.
Brown GD, Denning DW, Gow NA, Levitz SM, Netea MG, White TC. Hidden killers: human fungal infections. Sci Transl Med. 2012;4(165):165rv13.PubMed
2.
Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004;39(3):309–17.PubMedCrossRef
3.
Hadley S, Lee WW, Ruthazer R, Nasraway SAJ. Candidemia as a cause of septic shock and multiple organ failure in nonimmunocompromised patients. Crit Care Med. 2002;30(8):1808–14.PubMedCrossRef
4.
Opal SM, Garber GE, LaRosa SP, Maki DG, Freebairn RC, Kinasewitz GT, et al. Systemic host responses in severe sepsis analyzed by causative microorganism and treatment effects of drotrecogin alfa (activated). Clin Infect Dis. 2003;37(1):50–8.PubMedCrossRef
5.
6.
Kollef M, Micek S, Hampton N, Doherty JA, Kumar A. Septic shock attributed to Candida infection: importance of empiric therapy and source control. Clin Infect Dis. 2012;54(12):1739–46.PubMedCrossRef
7.
De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46(12):1813–21.PubMedCentralPubMedCrossRef
8.
Bassetti M, Marchetti M, Chakrabarti A, Colizza S, Garnacho-Montero J, Kett D, et al. A research agenda on the management of intra-abdominal candidiasis: results from a consensus of multinational experts. Intensive Care Med. 2013;39(12):2092–106.PubMedCrossRef
9.
Leroy O, Gangneux J-P, Montravers P, Mira J-P, Gouin F, Sollet J-P, et al. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005–2006). Crit Care Med. 2009;37(5):1612–8. doi:10.​1097/​CCM.​0b013e31819efac0​.PubMedCrossRef
10.
Skrobik Y, Laverdiere M. Why Candida sepsis should matter to ICU physicians. Crit Care Clin. 2013;29(4):853–64.PubMedCrossRef
11.
Kett DH, Azoulay E, Echeverria PM, Vincent JL. Extended Prevalence of Infection in ICU Study (EPIC II) Group of Investigators. Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study*. Crit Care Med. 2011;39(4):665–70. doi:10.​1097/​CCM.​0b013e318206c1ca​.PubMedCrossRef
12.
Pfaller MA, Messer SA, Moet GJ, Jones RN, Castanheira M. Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008–2009). Int J Antimicrob Agents. 2011;38(1):65–9.PubMedCrossRef
13.
Eggimann P, Garbino J, Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis. 2003;3(11):685–702.PubMedCrossRef
14.
Muskett H, Shahin J, Eyres G, Harvey S, Rowan K, Harrison D. Risk factors for invasive fungal disease in critically ill adult patients: a systematic review. Crit Care. 2011;15(6):R287.PubMedCentralPubMedCrossRef
15.
Ostrosky-Zeichner L, Pappas PG, Shoham S, Reboli A, Barron MA, Sims C, et al. Improvement of a clinical prediction rule for clinical trials on prophylaxis for invasive candidiasis in the intensive care unit. Mycoses. 2011;54(1):46–51.PubMedCrossRef
16.
Ostrosky-Zeichner L, Sable C, Sobel J, Alexander B, Donowitz G, Kan V, et al. Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis. 2007;26:271–6.PubMedCrossRef
17.
Ostrosky-Zeichner L. Invasive mycoses: diagnostic challenges. Am J Med. 2012;125(1 Suppl):S14–24.PubMedCrossRef
18.
Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB. Inflammatory response and clinical course of adult patients with nosocomial bloodstream infections caused by Candida spp. Clin Microbiol Infect. 2006;12(2):170–7.PubMedCrossRef
19.
Guzman JA, Tchokonte R, Sobel JD. Septic shock due to candidemia: outcomes and predictors of shock development. J Clin Med Res. 2011;3(2):65–71.PubMedCentralPubMed
20.
Shorr A, Tabak Y, Johannes R, Sun X, Spalding J, Kollef M. Candidemia on presentation to the hospital: development and validation of a risk score. Crit Care. 2009;13(5):1–10.CrossRef
21.
Meersseman W, Lagrou K, Spriet I, Maertens J, Verbeken E, Peetermans WE, et al. Significance of the isolation of Candida species from airway samples in critically ill patients: a prospective, autopsy study. Intensive Care Med. 2009;35(9):1526–31.PubMedCrossRef
22.
Clancy CJ, Nguyen MH. Finding the "missing 50 %" of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care. Clin Infect Dis. 2013;56(9):1284–92.PubMedCrossRef
23.
24.
Schuetz AN. Invasive fungal infections: biomarkers and molecular approaches to diagnosis. Clin Lab Med. 2013;33(3):505–25.PubMedCrossRef
25.
Karageorgopoulos DE, Vouloumanou EK, Ntziora F, Michalopoulos A, Rafailidis PI, Falagas ME. β-D-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis. Clin Infect Dis. 2011;52(6):750–70.PubMedCrossRef
26.
Tissot F, Lamoth F, Hauser PM, Orasch C, Flückiger U, Siegemund M, et al. β-glucan antigenemia anticipates diagnosis of blood culture-negative intraabdominal candidiasis. Ame J Respir Crit Care Med. 2013;188(9):1100–9.CrossRef
27.
Jansoniene O, White M. β-glucan antigenemia anticipates diagnosis of blood culture-negative intraabdominal candidiasis. Necessity Is the Mother of Invention. Ame J Respir Crit Care Med. 2013;188(9):1048–9.CrossRef
28.
Avni T, Leibovici L, Paul M. PCR diagnosis of invasive candidiasis: systematic review and meta-analysis. J Clin Microbiol. 2011;49:665–670.
29.
Bloos F, Bayer O, Sachse S, Straube E, Reinhart K, Kortgen A. Attributable costs of patients with candidemia and potential implications of polymerase chain reaction-based pathogen detection on antifungal therapy in patients with sepsis. J Crit Care. 2013;28(1):2–8.PubMedCrossRef
30.
Marinach-Patrice C, Fekkar A, Atanasova R, Gomes J, Djamdjian L, Brossas J-Y, et al. Rapid species diagnosis for invasive candidiasis using mass spectrometry. PLoS ONE. 2010;5(1):e8862.PubMedCentralPubMedCrossRef
31.
Huang AM, Newton D, Kunapuli A, Gandhi TN, Washer LL, Isip J, et al. Impact of Rapid organism identification via matrix-assisted laser desorption/ionization time-of-flight combined with antimicrobial stewardship team intervention in adult patients with bacteremia and candidemia. Clin Infect Dis. 2013;57(9):1237–45.PubMedCrossRef
32.
Neely LA, Audeh M, Phung NA, Min M, Suchocki A, Plourde D, et al. T2 Magnetic resonance enables nanoparticle-mediated rapid detection of candidemia in whole blood. Sci Transl Med. 2013;5(182):182ra54.PubMed
33.
Antworth A, Collins CD, Kunapuli A, Klein K, Carver P, Gandhi T, et al. Impact of an antimicrobial stewardship program comprehensive care bundle on management of candidemia. Pharmacother Pharmacother. 2013;33(2):137–43.CrossRef
34.
Kumar A, Ellis P, Arabi Y, Roberts D, Light B, Parrillo JE, et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest. 2009;136(5):1237–48.PubMed
35.
Patel GP, Simon D, Scheetz M, Crank CW, Lodise T, Patel N. The effect of time to antifungal therapy on mortality in candidemia associated septic shock. Am J Ther. 2009;16(6):508–11.PubMedCrossRef
36.
Zilberberg MD, Kollef MH, Arnold H, Labelle A, Micek ST, Kothari S, et al. Inappropriate empiric antifungal therapy for candidemia in the ICU and hospital resource utilization: a retrospective cohort study. BMC Infect Dis. 2010;10:150.PubMedCentralPubMedCrossRef
37.
Zilberberg MD, Kothari S, Shorr AF. Cost-effectiveness of micafungin as an alternative to fluconazole empiric treatment of suspected ICU-acquired candidemia among patients with sepsis: a model simulation. Crit Care. 2009;13(3):R94.PubMedCentralPubMedCrossRef
38.
Schuster MG, Edwards JJE, Sobel JD, Darouiche RO, Karchmer AW, Hadley S, et al. Empirical fluconazole versus placebo for intensive care unit patients: a randomized trial. Ann Intern Med. 2008;149(2):83–90.PubMedCrossRef
39.
Hanson KE, Pfeiffer CD, Lease ED, Balch AH, Zaas AK, Perfect JR, et al. β-D-glucan surveillance with preemptive anidulafungin for invasive candidiasis in intensive care unit patients: a randomized pilot study. PLoS ONE. 2012;7(8):e42282.PubMedCentralPubMedCrossRef
40.
Azoulay E, Dupont H, Tabah A, Lortholary O, Stahl JP, Francais A, et al. Systemic antifungal therapy in critically ill patients without invasive fungal infection*. Crit Care Med. 2012;40(3):813–22.PubMedCrossRef
41.•
Jaijakul S, Vazquez JA, Swanson RN, Ostrosky-Zeichner L. (1,3)-β-D-glucan as a prognostic marker of treatment response in invasive candidiasis. Clin Infect Dis. 2012;55(4):521–6. A clinical trial demonstrated that keeping track of serial BDG levels during antifungal therapy of patients with fungal sepsis has prognostic value.PubMedCrossRef
42.
Garnacho-Montero J, Diaz-Martin A, Garcia-Cabrera E, Ruiz Perez de Pipaon M, Hernandez-Caballero C, Lepe-Jimenez JA. Impact on hospital mortality of catheter removal and adequate antifungal therapy in Candida spp. bloodstream infections. J Antimicrob Chemother. 2013;68(1):206–13.PubMedCrossRef
43.•
Andes DR, Safdar N, Baddley JW, Playford G, Reboli AC, Rex JH, et al. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis. 2012;54(8):1110–22. A definitive study that showed how echinocandins and central line removal improved survival in patients with invasive candidiasis.PubMedCrossRef
44.
Nucci M, Anaissie E, Betts RF, Dupont BF, Wu C, Buell DN, et al. Early removal of central venous catheter in patients with candidemia does not improve outcome: analysis of 842 patients from 2 randomized clinical trials. Clin Infect Dis. 2010;51(3):295–303.PubMedCrossRef
45.
Clancy CJ, Nguyen MH. The end of an era in defining the optimal treatment of invasive candidiasis. Clin Infect Dis. 2012;54(8):1123–5.PubMedCrossRef
46.
Kaneko Y, Miyagawa S, Takeda O, Hakariya M, Matsumoto S, Ohno H, et al. Real-time microscopic observation of Candida biofilm development and effects due to micafungin and fluconazole. Antimicrob Agents Chemother. 2013;57(5):2226–30.PubMedCentralPubMedCrossRef
47.
Uppuluri P, Srinivasan A, Ramasubramanian A, Lopez-Ribot JL. Effects of fluconazole, amphotericin B, and caspofungin on Candida albicans biofilms under conditions of flow and on biofilm dispersion. Antimicrob Agents Chemother. 2011;55(7):3591–3.PubMedCentralPubMedCrossRef
48.
Nienaber JJC, Kusne S, Riaz T, Walker RC, Baddour LM, Wright AJ, et al. Clinical manifestations and management of left ventricular assist device-associated infections. Clin Infect Dis. 2013;57(10):1438–48.PubMedCrossRef
49.
Dellinger RP, Levy M, Rhodes A, Annane D, Gerlach H, Opal S, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2012. Intensive Care Med. 2013;39(2):165–228.PubMedCrossRef
50.•
Posteraro B, De Pascale G, Tumbarello M, Torelli R, Pennisi M, Bello G, et al. Early diagnosis of candidemia in intensive care unit patients with sepsis: a prospective comparison of (1->3)- β -D-glucan assay, Candida score, and colonization index. Crit Care. 2011;15(5):R249. The use of BDG assay at the beginning of sepsis demonstrated earlier positive test results than blood cultures. The test should help with early therapy of sepsis due to Candida.PubMedCentralPubMedCrossRef
51.
Lepak A, Andes D. Fungal sepsis: optimizing antifungal therapy in the critical care setting. Crit Care Clin. 2011;27(1):123–47.PubMedCrossRef
52.
Kett D, Shorr A, Reboli A, Reisman A, Biswas P, Schlamm H. Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: support for the 2009 IDSA treatment guidelines for candidiasis. Crit Care. 2011;15(5):1–7.CrossRef
53.
Pfaller MA, Messer SA, Woosley LN, Jones RN, Castanheira M. Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance. J Clin Microbiol. 2013;51(8):2571–81.PubMedCentralPubMedCrossRef
54.
Liu P, Ruhnke M, Meersseman W, Paiva JA, Kantecki M, Damle B. Pharmacokinetics of anidulafungin in critically ill patients with candidemia/invasive candidiasis. Antimicrob Agents Chemother. 2013;57(4):1672–6.PubMedCentralPubMedCrossRef
55.
Liu P. Population pharmacokinetic-pharmacodynamic analysis of anidulafungin in adult patients with fungal infections. Antimicrob Agents Chemother. 2013;57(1):466–74.PubMedCentralPubMedCrossRef
56.
Dupont BF, Lortholary O, Ostrosky-Zeichner L, Stucker F, Yeldandi V. Treatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B. Crit Care. 2009;13(5):R159.PubMedCentralPubMedCrossRef
57.
Guarascio A, Slain D, McKnight R, Petros K, Parker J, Wilson A, et al. A matched-control evaluation of an antifungal bundle in the intensive care unit at a university teaching hospital. Int J Clin Pharm. 2013;35(1):145–8.PubMedCrossRef
58.
Dimopoulos G, Antonopoulou A, Armaganidis A, Vincent JL. How to select an antifungal agent in critically ill patients. J Crit Care. 2013;28(5):717–27.PubMedCrossRef
59.
Alexander BD, Johnson MD, Pfeiffer CD, Jiménez-Ortigosa C, Catania J, Booker R, et al. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis. 2013;56(12):1724–32.PubMedCrossRef
60.
Ostrosky-Zeichner L. Editorial Commentary: Candida glabrata and FKS mutations: witnessing the emergence of the true multidrug-resistant Candida. Clin Infect Dis. 2013;56(12):1733–4.PubMedCrossRef
61.
Climo MW, Yokoe DS, Warren DK, Perl TM, Bolon M, Herwaldt LA, et al. Effect of daily chlorhexidine bathing on hospital-acquired infection. N Engl J Med. 2013;368(6):533–42.PubMedCrossRef
Metadata
Title
Candida Sepsis: a New Entity?
Authors
Juan Pablo Caeiro
Fernando Riera
Publication date
01-03-2014
Publisher
Springer US
Published in
Current Fungal Infection Reports / Issue 1/2014
Print ISSN: 1936-3761
Electronic ISSN: 1936-377X
DOI
https://doi.org/10.1007/s12281-013-0171-9

Other articles of this Issue 1/2014

Current Fungal Infection Reports 1/2014 Go to the issue

Pediatric Fungal Infections (T Lehrnbecher, Section Editor)

Current Epidemiology and Management of Invasive Candidiasis in Infants

Current Management of Fungal Infections (L Ostrosky-Zeichner, Section Editor)

Diagnosis of Candidemia

Current Management of Fungal Infections (L Ostrosky-Zeichner, Section Editor)

Cryptococcus gattii Infections and Virulence

Pediatric Fungal Infections (T Lehrnbecher, Section Editor)

Pneumocystis Pneumonia: Epidemiology and Options for Prophylaxis in Non-HIV Immunocompromised Pediatric Patients

Pediatric Fungal Infections (T Lehrnbecher, Section Editor)

Rare Fungal Infections in Children: An Updated Review of the Literature

Hot Topic

Macrophage–Cryptococcus Interactions: An Update
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits